Multiple Myeloma News
The presence of circulating tumor plasma cells by next-generation flow independently predicted disease progression after treatment in patients with multiple myeloma.
The detection of chromosomal aberrations in the main clone appear to have prognostic significance in patients with smoldering myeloma.
A retrospective analysis sought to determine the association between myeloproliferative neoplasms, MPN-directed therapy, and development of splanchnic vein thrombosis.
The TEAMM trial sought to assess time to first febrile episode or death from all causes in patients with newly diagnosed myeloma who received antibiotic prophylaxis vs those who did not.
Researchers explored a possible link between TNF-α and peripheral neuropathy in patients with MM treated with bortezomib.
The addition of plerixafor to treatment following transplantation may not enhance lymphocyte recovery in patients with multiple myeloma.
Uncertainty is defined in this study as “the inability to give sense or meaning to the processes or situations that have to do with medical conditions.”
Only about one-third of patients required hospital admission.
These characteristics may account for enhanced antitumor efficacy in multiple myeloma.
Patients who received intensification treatment experienced longer progression-free survival compared with patients receiving maintenance treatment.
Patients receiving the 3-drug treatment experienced increasing rates of complete response and measurable residual disease from induction through consolidation.
A hematologic score based on specific blood parameters was evaluated for its potential to predict survival in patients with newly diagnosed multiple myeloma.
Patients receiving treosulfan and fludarabine experienced improved event-free and overall survival compared with patients receiving busulfan and fludarabine.
Time to initiation of therapy was significantly longer for black and Hispanic patients compared with white patients.
This study assessed levels of adherence to antihypertensive, lipid-lowering, and antidiabetic therapy in patients initiating oral oncology therapy for a hematologic cancer.
Prolonged closure time and defects in von Willebrand factor were identified as risk factors for bleeding complications patients with multiple myeloma.
A critical step in the preparation of autologous CAR-T therapy is the ex vivo proliferation of T cells from samples obtained from leukapheresis.
In this systematic review, researchers analyzed the cost effectiveness of various treatments and treatment lines for multiple myeloma.
A case series study demonstrated the importance of timely, preventive dental assessment for patients with multiple myeloma.
The prognostic value of MRD in the setting of multiple myeloma has been previously demonstrated, although questions remain regarding MRD detection methodology.